The drug, Kisunla, made by Eli Lilly, is the latest in a new class of treatments that could modestly slow cognitive decline in initial stages of the disease but also carry safety risks.
Category: Clinical Trials
-
Embattled Alzheimer’s Researcher Is Charged With Fraud
Hoau-Yan Wang, a professor at City College, published studies supporting simufilam, now in advanced clinical trials.
-
Gilead Shot Provides Total Protection From HIV in Trial of Young African Women
An injection given just twice a year could herald a breakthrough in protecting the population that has the highest infection rates.
-
How A.I. Is Revolutionizing Drug Development
In high-tech labs, workers are generating data to train A.I. algorithms to design better medicine, faster. But the transformation is just getting underway.
-
Advisory Panel of Experts Endorses F.D.A. Approval of New Alzheimer’s Drug
The modest benefits of the treatment, donanemab, made by Eli Lilly, outweigh the risks, the panel concluded unanimously.
-
FDA Reviews MDMA Therapy for PTSD, Citing Health Risks and Study Flaws
The agency’s staff analysis suggests that approval of the illegal drug known as Ecstasy for treatment of PTSD is far from certain, with advisers meeting next week to consider the proposed therapy.
-
Setback Deals Blow to Neuralink’s First Brain Implant Patient, but He Stays Upbeat
Elon Musk’s first human experiment with a computerized brain device developed significant flaws, but the subject, who is paralyzed, has few regrets.
-
FDA Approves Amgen Drug for Persistently Deadly Form of Lung Cancer
The treatment is for patients with small cell lung cancer, which afflicts about 35,000 people in the U.S. a year.
-
A.L.S. Drug Relyvrio Will Be Taken Off the Market, Its Maker Says
Results of a large clinical trial found the treatment did not work any better than a placebo.
-
A.L.S. Drug Relyvrio Fails Clinical Trial and May Be Withdrawn From the Market
Leaders of the treatment’s manufacturer, Amylyx, said they would announce their plans for it within eight weeks.
-
Powerful Psychedelic Drug Gains New Notice as an Opioid Addiction Therapy
New research is stirring interest in ibogaine, which appears to help ease the agony of detox and prevent relapse. Used in other countries, it remains illegal in the U.S.
-
Powerful Psychedelic Drug Gains New Notice as an Opioid Addiction Therapy
New research is stirring interest in ibogaine, which appears to help ease the agony of detox and prevent relapse. Used in other countries, it remains illegal in the U.S.